After Recent Schedule III Listing, Cannabis Operators Request Urgent Tax Clarity on 280E

WASHINGTON — Cannabis companies are calling on federal tax authorities to quickly explain how the recent move of medical marijuana to a less restrictive drug category will change their ability to claim standard business expenses.

In late April, the Treasury Department and IRS stated they intend to provide official instructions for state-approved medical cannabis providers looking to benefit from changes to Section 280E. This provision has barred most typical tax deductions for cannabis operators because the plant was previously placed on Schedule I of the Controlled Substances Act.

The push for faster details follows the federal decision to reclassify certain medical cannabis products to Schedule III. A group of seven House Democrats recently sent a formal letter to Treasury Secretary Scott Bessent and top IRS officials, asking them to deliver the promised information without delay.

Lawmakers highlighted in their message that straightforward instructions would minimize conflicts during tax reviews and promote fair application of the rules industry-wide. They requested particular focus on two frequent business models: operators working under one license that includes both medical and recreational sales, and those managing distinct licenses for each type of market.

The letter notes that "State-legal cannabis businesses have been denied ordinary business tax deductions and credits due to Section 280E." It further recommends that Treasury and IRS officials partner with the Small Business Administration to distribute the guidance effectively to everyone who needs it.

The financial impact of these rules has been substantial for the sector. Under Section 280E, many cannabis firms have faced unusually high federal tax burdens for years because basic operating expenses — such as facility leases, staff wages, advertising and inventory costs — could not be subtracted. The Schedule III adjustment is expected to offer meaningful relief for qualifying medical programs.

Mixed-market operators, who handle both medical and adult-use customers, encounter added complexity. They will require precise methods for separating allowable and non-allowable expenses. Lacking that direction, they could face increased scrutiny from auditors or unexpected compliance issues.

Officials have not yet indicated when the guidance might be issued. This uncertainty is complicating tax planning and quarterly reporting for many businesses.

The Democratic representatives who signed the letter described the rescheduling as a significant update to federal tax treatment of the cannabis field. They cautioned that prolonged waiting periods might create avoidable difficulties for smaller enterprises already managing diverse state-level requirements.

Adult-use cannabis continues to fall under Schedule I restrictions, so those activities remain subject to the full limitations of Section 280E. This targeted shift for medical products stands as one of the more notable federal adjustments to cannabis policy in recent memory.